CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
CANADA

About Us

Conference

Partner With Us

  • APAC
    • US
    • EUROPE
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    Bioinformatics & Genomics
    BioTech
    Cell and Gene Therapy
    Drug Discovery and Development
    Life Science AI
    Next-Generation Sequencing
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    CDMO
    Cosmetic
    CRO
    Life Science Testing And Compliance
    Supplement Manufacturing
  • Business Services
    Life Science Consulting
    Life Sciences Marketing and Communication
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Teva Pharmaceuticals

Timothy White, Vice President & Head of Global Digital Commercial

Avoiding the 'Shiny object' Trap of Digital Transformation

Timothy White

Timothy White

Digital commercial transformation in life sciences often gets caught in the ‘shiny object’ trap. Undoubtedly any new technology or trend to hit the market will, within a period of months, make its way into some consultant’s slide deck or on the agenda of an industry event with bold claims of ‘how this new thing will fundamentally disrupt pharma’s commercial model.’ In my personal experience ‘transformation’ is more often about consistently delivering on a new set of fundamentals rather than aimlessly searching for a competitive advantage through a singular technology or initiative. These fundamentals, much like a healthy diet or exercise regime, are often difficult to initiate but overtime become routine and results start to show. While not an exhaustive list, here are three fundamentals to follow to ensure that real value can be obtained from digital commercial transformation efforts.


1.) ‘Relationship first’ –Any go-to-market approach should always be grounded in building strong customer relationships, this is what sales representatives have done so successfully for decades. In digital this is easily lost as marketers look to ‘blast eMails to target lists’ or ‘optimize their conversion funnels using advanced cloud-based technology’. We should learn from other sectors who truly think ‘relationship first.’ Utilize digital approaches to build stronger customer relationships through personalized self-service approaches or by providing a truly ‘omnichannel’ experience for product promotion. Done-well these approaches both provide a more efficient commercial model and improve the overall customer relationship. Before initiating any new digital initiative or technology investment, ask the question ‘will this build a stronger relationship between our brand and the customer?’ If the answer is unsure, you might want to head back to the whiteboard.


2.) ‘Follow The 4-Es’ – ‘Content is king/queen’ is one of the most repeated best practices in digital engagement; what this phrase doesn’t share however is exactly how to ‘coronate’ your content. A fundamental to follow here is to remember the 4-E’s: engaging, emotional, entertaining, and educational.


Pharma teams, rightfully so, are complete experts in producing educational content, however in the digital world if your content or service doesn’t at least tick one of the other ‘E’s’, you’ll quickly lose your customer’s attention; technology solutions should only serve to enable this.


3.) ‘Think future back’ – It’s easy in the standard planning cycles of major corporations to get stuck only looking at near-term opportunities without projecting longer-term value-creation from digital transformation efforts. A way to avoid this is to use a bit of ‘futurist’ thinking: analyze current trends in customer behavior and technology, look 3-5 years ahead and create a ‘preferred’ view on how your company should ‘win’ in future customer engagement, take into account the first two fundamentals and then decide what needs to be done tomorrow to achieve this future. Notably this should provide a very simple ‘decision making criteria’ to avoid the aforementioned ‘shiny object trap’ for all future investments or experiments.


Transformation’ is more often about consistently delivering on a new set of fundamentals rather than aimlessly searching for a competitive advantage through a singular technology or initiative


While advancements in commercial technology have had a profound impact on go-to-market models this past decade, given all the dramatic events of 2020 this impact will undoubtedly only grow more significant in the years ahead. With that in mind it’s more important than ever to discern what digital transformation activities drive real customer value and competitive advantage and what are simply more ‘shiny objects.’


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review APAC
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review APAC. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreviewapac.com/leadership-perspective/avoiding-the--shiny-object--trap-of-digital-transformation-nwid-859.html